Trametinib and Dabrafenib in histiocytic sarcoma transdifferentiated from chronic lymphocytic leukemia with a K-RAS and a unique BRAF mutation

Rassidakis, Georgios Z.; Stromberg, Olga; Xagoraris, Ioanna; Jatta, Kenbugul; Sonnevi, Kristina

doi:10.1007/s00277-020-03941-7

Cited by 7 publications

(7 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have reported an association with other previous or simultaneous hematologic malignancies, such as low-grade B-cell lymphomas or B-or T-cell lymphoblastic leukemia, and rarely with mediastinal germ cell tumors. In these cases, HS and previous or concomitant hematologic malignancies share the identical clonal alteration, thereby supporting the hypothesis of transdifferentiation of the same malignant hematologic progenitor [8][9][10][11].…”

Section: Discussionsupporting

confidence: 71%

“…In our patient, persistent and severe hematuria, as well as the demonstration of a localized disease at presentation, prompted the use of cystoprostatectomy. However, recent reports of dramatic responses to adenosine-triphosphate-competitive inhibitors of BRAF kinase (i.e., vemurafenib and dabrafenib) alone or in combination with mitogen-activated protein kinase kinase (MEK) inhibitor trametinib, in the subset of BRAF-mutated HS, are paving the way to targeted/tailored therapy [10][11]. In our patient, targeted therapy was not attempted because no druggable genetic alterations (BRAF, NRAS, and KRAS) was found.…”

Section: Discussionmentioning

confidence: 85%

See 1 more Smart Citation

Original Observation of Primary Bladder Histiocytic Sarcoma: First Case Report

Nicola

Onorati

Lancia

et al. 2021

Cureus

View full text Add to dashboard Cite

Histiocytic sarcoma (HS) is a rare malignant lymphohematopoietic neoplasm; it has been cited in the recent World Health Organization (WHO) classification as a malignant proliferation of cells exhibiting morphological and immunophenotypic features of mature histiocytes. To our knowledge, the present case is the first to be described in the bladder of a patient without a history of lymphoma. Only one case has been reported so far regarding a secondary bladder presentation in the setting of a previous diffuse large B-cell lymphoma. We discuss the case of a 68-year-old male who presented with hematuria and dysuria. CT scan revealed a 4-cm intravesical mass that histological examination defined as HS. Our objective was to describe the clinical, histological, immunophenotypical, molecular characteristics and discuss the differential diagnoses of this first case of primary bladder HS. Our research was based on a review of selected articles obtained via the PubMed database. This extremely rare experience provided us with the opportunity to depict an interesting case, highlight its uniqueness, and build up new pathological evidence.

show abstract

Section: Discussionsupporting

confidence: 71%

Section: Discussionmentioning

confidence: 85%

Original Observation of Primary Bladder Histiocytic Sarcoma: First Case Report

Nicola

Onorati

Lancia

et al. 2021

Cureus

View full text Add to dashboard Cite

show abstract

“…The hematologist advised that trametinib[ 11 , 12 ] and/or imatinib[ 13 ] could be beneficial in this patient. It has been reported that chronic myeloid leukemia, other types of leukemia and HS present similar medical features[ 10 , 14 ]. These features might be therapeutic targets for imatinib.…”

Section: Treatmentmentioning

confidence: 99%

Multiple disciplinary team management of rare primary splenic malignancy: Two case reports

Luo¹,

Wang²,

Xiao³

et al. 2022

World J Clin Cases

View full text Add to dashboard Cite

BACKGROUND Malignant splenic tumors are rare but fatal, presenting a challenge in diagnosis and management involving hematology, oncology, and general surgery. By contrast, diagnosing and treating other common malignant tumors (such as lung and gastrointestinal cancer) offers multiple strategies for chemotherapy, radiotherapy, targeted therapy, and immunotherapy with the prospect of a cure. With various specialists involved in clinical multiple disciplinary team (MDT) discussion, personal bias can be minimized. It can also ignite important discussion which can benefit not only one patient but many patients. CASE SUMMARY Here, we report on the MDT diagnosis and management of the malignant splenic tumors littoral cell angiosarcoma and histiocytic sarcoma. Although only two cases of rare primary splenic malignancy are presented, MDT is a novel means of rare disease treatment. CONCLUSION To benefit patients, imaging analysis, safe operation, precise pathology examination, and individualized therapeutic treatment strategies are required. The involvement of various specialists in a clinical MDT discussion minimizes personal bias and can create important ideas to benefit all patients.

show abstract

“…Thus, whenever HS is encountered, underlying neoplasms should be sought and if possible, genetic comparisons between the lesions should be performed as appropriate ( 24 ). Interestingly, there is some evidence that HS arising from an underlying non-histiocytic neoplasm may be related to acquisition of additional MAPK related mutations superimposed on the genome of the originating neoplasm ( 25 ). Cases in which no pre-existing neoplasm can be identified may be considered de novo .…”

Section: Histiocytic Sarcomamentioning

confidence: 99%

Histiocytic and dendritic cell neoplasms of the mediastinum

Baraban¹,

Cooper²

2020

Mediastinum

View full text Add to dashboard Cite

In this review, we discuss a logical approach to diagnosis of histiocytic and dendritic cell lesions of the mediastinum. We break down the differential diagnosis between true neoplasms of histiocytic and dendritic cells [Rosai-Dorfman disease (RDD), Langerhans cell histiocytosis (LCH), and follicular dendritic cell sarcoma (FDCS)] versus selected neoplasms of other lineages which frequently attract non-neoplastic histiocytes or resemble them morphologically (carcinoma, melanoma, sarcoma, germinoma, mesothelioma, and lymphoma). As neoplasms in the latter category are more common, they should be stringently excluded before diagnosing a lesion in the first group, particularly given enormous differences in clinical management. We also consider histiocytic sarcoma (HS), an extremely rare lesion which, in some cases is likely of intrinsic histiocytic differentiation, whereas in others represents clonal evolution from an underlying non-histiocytic neoplasm.

show abstract

Trametinib and Dabrafenib in histiocytic sarcoma transdifferentiated from chronic lymphocytic leukemia with a K-RAS and a unique BRAF mutation

Cited by 7 publications

References 7 publications

Original Observation of Primary Bladder Histiocytic Sarcoma: First Case Report

Original Observation of Primary Bladder Histiocytic Sarcoma: First Case Report

Multiple disciplinary team management of rare primary splenic malignancy: Two case reports

Histiocytic and dendritic cell neoplasms of the mediastinum

Contact Info

Product

Resources

About